1.Avram,B.,F.Arjen.,D.Tine andV.Yvan.2000. Effects of Cisapride on Corrected QT Interval,Heart Rate, and Rhythm in Infants Undergoing Polysomnography. Pediatrics106 (6): 85.
2.Ahmed, S.R.1995. Cisapride and torsades de pointes.The Lancet. 345-508.
3.AlWabel,N.A.,Strauch.,S.M.Keene.,B.W.Nakayama.,N.Hamlin.2002.Electrocardiographic and Hemodynamic Effects of Cisapride Alone and Combined with Erythromycin in Anesthetized Dogs. Cardiovascular Toxicology:195- 207.
4.Diego,J.,M.D.Belardinelli.,L.Antzelevitch,C.2003.Cisapride-InducedTransmural Dispersion of Repolarization and Torsade de Pointes in the Canine Left Ventricular Wedge Preparation During Epicardial Stimulation. Circulation:108.1027.
5.Dowling,P.M.1995.Prokinetic drugs: metoclopramide and cisapride. Canad.Vet.J: 115-116.
6.Hondeghem,L.M and D.L.Synders.1990.Class III antiarrhythmic drugs have a lot of potential but a long way to go: reduced efffectiveness and dangers of reverse use – dependence. Circulation: 686-690.
7.Kuroda,T.,y.Yoshihara.,H.Nakamura.1992.Effects of cisapride on gastrointestinal motor activity and gastric emptying of disopyramide. J. Pharmaco-Dyn:395-402.
8.Libby,P.,R.O.Bonow.,D.L. Mann.,D.P. Zipes.2008.Braunwald's Heart Disease, Eighth Ed, Philadelphia, Saunders Elsevier:149-974.
9.Liu,S.,R.B., Melchert.,R.H and Kennedy.1997. Inhibition of L-type Ca 2+ channel current in rat ventricular mycoytes by terfenadine. Circ Res: 202-210.
10.Nolan,E.R.,M.R.Feng.,J.R. Koup.,J. Liu.,D. Turluck.,Y. Zhang and et al.2006. A novel predictive pharmacokinetic/pharmacodynamic model of repolarization prolongation derived from the effects of terfenadine, cisapride and E-4031 in the conscious chronic av node-ablated, His bundle-paced dog. J Pharmacol Toxicol Methods:1-10.
11. O'Rourke, R.A. Walsh and V. Fuster.2009. Hurst's The Heart.12 ed. pp.90-216,in: canada.. McGraw-Hill.
12.Sugiyama, A and K.Hashimoto.1998.Effects of gastrointestinal prokinetic agents, TKS159 and cisapride, on the in situ canine heart assessed by cardiohemodynamic and electrophysiological monitoring. Toxicol Appl Pharmacol:261-9.
13.Trevor,J.,B.G Katzung and B.Susan, B.2007. Examination and Board Review, 1 ed.PP.359-472. Katzung & Trevor's Pharmacology McGraw-Hill Professional.
14.Wong, W.,H.N. Pavlou., U.M, Birgersdotter., D.E, Hilleman., S.M, Mohiuddin and D.M Roden.1992.Pharmacology of the class III antiarrhythmic agent sematilide in patients with arrhythmia. Am J Cardiol :206-212.
15. Yue,Y and et Al.2015.Pathogenesis of the Novel Autoimmune-Associated Long QT Syndrome. Circulation :115.